Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties.
Company Information
About this company
Key people
Robert J. Hariri
Chairman of the Board, Chief Executive Officer
John Sprague
Acting Chief Financial Officer
Peter H. Diamandis
Independent Director
Vincent Levien
Independent Director
Shiu Fei Ling
Independent Director
Diane L. Parks
Independent Director
Click to see more
Key facts
- Shares in issue28.95m
- EPICCELU
- ISINUS1511902041
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$25.47m
- Employees115
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.